Article

Article-Optimizing Clinical Supply for a Smoother Phase 2a to 2b Transition

Each phase of a clinical study has unique supply challenges. When Phase 2 is split into multiple parts, specific clinical supply needs may vary from Phase 2a to Phase 2b. Important supply decisions for 2a need to be made with 2b in mind to help ensure a more seamless transition so as to minimize costs and avoid time delays.

Learn more about:

The reasons behind implementing a multi-segment Phase 2 study

The similarities and differences between Phases 2a and 2b

The implications that Phase 2b supply requirements can have on Phase 2a kit design specifications.

Business Email Address*

First Name*

Last Name*

Company*

Title*

Business Phone

Country

State or Province

Buying Horizon*

Asset ID

Asset Type

Asset URL

Download Center - Date Stamp

Download Center - Visit Count

ZZ - Last SFDC Campaign ID

Unique ID

Browser

auxCountry

auxState

Why Catalent?

Catalyst + Talent

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of more than 7,000 products to over 1,000 customers annually. Catalent’s expert workforce exceeds 17,000, including more than 2,500 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year. For more information, visit www.catalent.com.

More products. Better treatments. Reliably supplied.™